Floatz logo

hyoscine-n-butyl bromide

Ovarian Carcinoma

Universitaire Ziekenhuizen KU LeuvenSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

60 Active assets in the Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Palbociclib
University Medical Center Groningen
Phase 4BB
Docetaxel
Case Comprehensive Cancer Center
Phase 3BB
Eloxatin
Moscow Regional Oncological Dispensary
Phase 3BB
su011248
University Medical Center Groningen
Phase 4B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

hyoscine-n-butyl bromide is also rated in:

ColicDormant
B
Indicative ·
57 / 100
View asset →
endometrial carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →